Non-alcoholic fatty liver disease (NASH) is rarely diagnosed in primary care or diabetology clinics, but new guidance from the National Institute for Health and Care Excellence (NICE) could help change that. NICE found that the non-invasive technology from Echosens is a safe and effective way to improve patient outcomes and create a more efficient system for diagnosing liver disease in the early stages.
“With the incidence of liver disease rising at staggering rates, more needs to be done to catch and diagnose it early. When you look at the cost burden of liver disease and the high death rate, bringing this 10-minute scan to primary care visits is something that should be adopted on a much larger scale.” - Dominique Legros, Echosens Group CEO
On 22 May 2023, policymakers, thought leaders, Permanent Mission Representatives to the UN, WHO staff, and people affected by liver disease will gather at the EASL Office in Geneva for the invitation...
Rising obesity rates combined with unhealthy habits developed during the pandemic has led to an increase in some concerning diseases affecting the liver that has clinicians concerned. Check out this interactive interview with HCPLive, where Dr. Alkhouri discusses his use of the FibroScan® technology to improve care of patients with NAFLD and NASH at Arizona Liver Health. 👉Watch the interview here: www.hcplive.com/view/alkhouri-improving-nash-diagnosis-fibroscan... See MoreSee Less
The future of diagnosing and monitoring NAFLD/NASH could be #noninvasive. Learn more about that topic by reading the full article published in Pharma Technology Focus magazine. #FibroScan® is mentioned as a non-invasive technology used for detecting and diagnosing #NAFLD in high-risk individuals, including type 2 diabetes patients. 👉 www.pharmaceutical-technology.com/comment/diagnosing-and-monitoring-nafld-nash/